Patents by Inventor Ian Hampson

Ian Hampson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 12083120
    Abstract: The present invention concerns pharmaceutical compositions formulated for dermal application comprising a therapeutically effective amount of lopinavir and ritonavir in a pharmaceutically acceptable vehicle and wherein the weight ratio (w/w) of lopinavir:ritonavir is between 9:1 and 18:1. Such compositions are useful for treating, or preventing, skin cancers and premalignant dermal conditions.
    Type: Grant
    Filed: May 23, 2019
    Date of Patent: September 10, 2024
    Assignee: Douglas Pharmaceuticals LTD.
    Inventors: Ian Hampson, Lynne Hampson
  • Publication number: 20240148729
    Abstract: The present invention concerns pharmaceutical compositions formulated for topical application that are useful in the treatment of HPV-related pathologies and in particular the treatment of premalignant and malignant conditions of the cervix. The compositions comprise a therapeutically effective amount of lopinavir and ritonavir in a pharmaceutically acceptable vehicle and wherein the weight ratio (w/w) of lopinavir:ritonavir is between 9:1 and 18:1.
    Type: Application
    Filed: June 30, 2023
    Publication date: May 9, 2024
    Applicant: DOUGLAS PHARMACEUTICALS LIMITED
    Inventors: Ian Hampson, Lynne Hampson
  • Patent number: 11738024
    Abstract: The present invention concerns pharmaceutical compositions formulated for topical application that are useful in the treatment of HPV-related pathologies and in particular the treatment of premalignant and malignant conditions of the cervix. The com-positions comprise a therapeutically effective amount of lopinavir and ritonavir in a pharmaceutically acceptable vehicle and wherein the weight ratio (w/w) of lopinavir: ritonavir is between 9:1 and 18:1.
    Type: Grant
    Filed: May 23, 2019
    Date of Patent: August 29, 2023
    Assignee: Douglas Pharmaceuticals Limited
    Inventors: Ian Hampson, Lynne Hampson
  • Publication number: 20220257771
    Abstract: Provided herein are methods and compositions for treating and/or inhibiting the development or progression of conditions caused by, or associated with, Herpes Simplex Virus (HSV)infection. In particular, provided are compositions comprising lopinavir alone, or lopinavir and ritonavir, methods for their manufacture; and the use of said pharmaceutical compositions as a medicament. In particular, pharmaceutical compositions are provided for use in treating and/or inhibiting the progression of HSV related conditions.
    Type: Application
    Filed: May 20, 2020
    Publication date: August 18, 2022
    Applicant: DOUGLAS PHARMACEUTICALS LIMITED
    Inventors: Ian Hampson, Lynne Hampson, Fergus Cameron Binnie, Peter Surman
  • Publication number: 20210213015
    Abstract: The present invention concerns pharmaceutical compositions formulated for topical application that are useful in the treatment of HPV-related pathologies and in particular the treatment of premalignant and malignant conditions of the cervix. The compositions comprise a therapeutically effective amount of lopinavir and ritonavir in a pharmaceutically acceptable vehicle and wherein the weight ratio (w/w) of lopinavir: ritonavir is between 9:1 and 18:1.
    Type: Application
    Filed: May 23, 2019
    Publication date: July 15, 2021
    Applicant: DOUGLAS PHARMACEUTICALS LIMITED
    Inventors: Ian Hampson, Lynne Hampson
  • Publication number: 20210213016
    Abstract: The present invention concerns pharmaceutical compositions formulated for dermal application comprising a therapeutically effective amount of lopinavir and ritonavir in a pharmaceutically acceptable vehicle and wherein the weight ratio (w/w) of lopinavir: ritonavir is between 9:1 and 18:1. Such compositions are useful for treating, or preventing, skin cancers and premalignant dermal conditions.
    Type: Application
    Filed: May 23, 2019
    Publication date: July 15, 2021
    Applicant: DOUGLAS PHARMACEUTICALS LTD
    Inventors: Ian Hampson, Lynne Hampson
  • Patent number: 10251884
    Abstract: Disclosed herein are compositions comprising lopinavir alone or in combination with ritonavir for use as a medicament in the treatment of cancer or benign proliferative disorders (warts) or in the prevention of the development of cancer. Pharmaceutical compositions formulated for topical application comprising a therapeutically effective amount of lopinavir or a therapeutically effective amount lopinavir and ritonavir in a pharmaceutically acceptable vehicle are also provided. Also disclosed are methods of treating a patient having an HPV related dysplasia of the cervix comprising administering to said patient a therapeutically effective dose of the disclosed pharmaceutical compositions.
    Type: Grant
    Filed: September 5, 2017
    Date of Patent: April 9, 2019
    Assignee: The University of Manchester
    Inventors: Ian Hampson, Lynne Hampson
  • Publication number: 20180161328
    Abstract: Disclosed herein are compositions comprising lopinavir alone or in combination with ritonavir for use as a medicament in the treatment of cancer or benign proliferative disorders (warts) or in the prevention of the development of cancer. Pharmaceutical compositions formulated for topical application comprising a therapeutically effective amount of lopinavir or a therapeutically effective amount lopinavir and ritonavir in a pharmaceutically acceptable vehicle are also provided. Also disclosed are methods of treating a patient having an HPV related dysplasia of the cervix comprising administering to said patient a therapeutically effective dose of the disclosed pharmaceutical compositions.
    Type: Application
    Filed: September 5, 2017
    Publication date: June 14, 2018
    Applicant: The University of Manchester
    Inventors: Ian Hampson, Lynne Hampson
  • Patent number: 9782409
    Abstract: Disclosed herein are compositions comprising lopinavir alone or in combination with ritonavir for use as a medicament in the treatment of cancer or benign proliferative disorders (warts) or in the prevention of the development of cancer. Pharmaceutical compositions formulated for topical application comprising a therapeutically effective amount of lopinavir or a therapeutically effective amount lopinavir and ritonavir in a pharmaceutically acceptable vehicle are also provided. Also disclosed are methods of treating a patient having an HPV related dysplasia of the cervix comprising administering to said patient a therapeutically effective dose of the disclosed pharmaceutical compositions.
    Type: Grant
    Filed: October 23, 2014
    Date of Patent: October 10, 2017
    Assignee: The University of Manchester
    Inventors: Ian Hampson, Lynne Hampson
  • Publication number: 20160271132
    Abstract: Disclosed herein are compositions comprising lopinavir alone or in combination with ritonavir for use as a medicament in the treatment of cancer or benign proliferative disorders (warts) or in the prevention of the development of cancer. Pharmaceutical compositions formulated for topical application comprising a therapeutically effective amount of lopinavir or a therapeutically effective amount lopinavir and ritonavir in a pharmaceutically acceptable vehicle are also provided. Also disclosed are methods of treating a patient having an HPV related dysplasia of the cervix comprising administering to said patient a therapeutically effective dose of the disclosed pharmaceutical compositions.
    Type: Application
    Filed: October 23, 2014
    Publication date: September 22, 2016
    Applicant: The University of Manchester
    Inventors: Ian HAMPSON, Lynne HAMPSON
  • Publication number: 20130046098
    Abstract: The present invention relates to compounds of formula (I): wherein A=formula: (a) or formula: (b); X is oxygen or methylene; Y is C3-6 alkyl or aryl; Z is oxygen or C1-3 alkyl; R1 is hydrogen or C1-3 alkyl; R2 is hydrogen or C1-3 alkyl; the or each R3 is separately C1-3 alkyl or halo; the or each R4 is separately C1-3 alkyl or halo; p is 0 to 4; q is 0 to 4; m is 0 or 1; and n is 1 to 3. These compounds are useful as kinase inhibitors for the treatment of cancer and other diseases.
    Type: Application
    Filed: August 20, 2010
    Publication date: February 21, 2013
    Applicant: THE UNIVERSITY OF MANCHESTER
    Inventors: Lynne Hampson, Ian Hampson, John Anthony Hadfield, Timothy Patrick Kemp, Alan Thomson McGowan
  • Publication number: 20050233310
    Abstract: The present invention relates to a method of screening a protein for involvement in cancer. The method involves the steps of: exposing the protein to a first viral oncoprotein; assaying for interaction of the protein and the first viral oncoprotein; exposing the protein to a second viral oncoprotein; and assaying for interaction of the protein and the second viral oncoprotein. Interaction of the protein with the viral oncoproteins indicates that the protein is involved in cancer.
    Type: Application
    Filed: March 11, 2003
    Publication date: October 20, 2005
    Inventors: Ian Hampson, Lynne Hampson